Metabolic Phase 3 Readout Calendar
Industry-sponsored metabolic trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
42
Next 6 months
70
Next 12 months
22
Results posted
300
Phase 3 Metabolic
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 metabolic trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What metabolic trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 metabolic trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which metabolic trials have already read out?
The "recently read out" section shows Phase 3 metabolic trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Metabolic slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Metabolic landscape →
Recently read out & awaiting topline — Metabolic
· 39Phase 3 metabolic trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Completed | Q1 2026 2026-03-16 | Completed · awaiting
Updated 3mo ago
| NCT05803421 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes | Completed | Q1 2026 2026-03-04 | Completed · awaiting
Updated 3mo ago
| NCT06221969 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Completed | Q1 2026 2026-02-03 | Completed · awaiting
Updated 3mo ago
| NCT06235086 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Completed | Q1 2026 2026-01-23 | Completed · awaiting
Updated 4mo ago
| NCT06258148 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Asset: Retatrutide | Diabetes Type 2 | Completed | Q1 2026 2026-01-22 | Completed · awaiting
Updated 4mo ago
| NCT06354660 |
| Eli Lilly and Company | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Asset: Tirzepatide | Overweight +1 | Completed | Q1 2026 2026-01-20 | Completed · awaiting
Updated 4mo ago
| NCT06047548 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab | Psoriasis +1 | Completed | Q1 2026 2026-01-08 | Completed · awaiting
Updated 6mo ago
| NCT06588283 |
| Bayer | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema Asset: 8 mg aflibercept (BAY 86-5321) (High Dose) | Diabetic Macular Edema | Completed | Q4 2025 2025-12-29 | Completed · awaiting
Updated 4mo ago
| NCT06422507 |
| Rhythm Pharmaceuticals, Inc. | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Asset: Setmelanotide | Obesity +1 | Active Not Recruiting | Q4 2025 2025-12-22 | Completed · awaiting
Updated 5mo ago
| NCT05093634 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity +1 | Completed | Q4 2025 2025-12-12 | Completed · awaiting
Updated 3mo ago
| NCT06066528 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Asset: Cagrilintide | Obesity | Completed | Q4 2025 2025-12-08 | Completed · awaiting
Updated 5mo ago
| NCT06131437 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Asset: Survodutide | Obesity | Completed | Q4 2025 2025-12-03 | Completed · awaiting
Updated 7mo ago
| NCT06176365 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Completed | Q4 2025 2025-12-02 | Completed · awaiting
Updated 4mo ago
| NCT06066515 |
| Vincentage Pharma Co., Ltd | A Research Study of VCT220 in Adult Chinese Participants With Obesity Asset: VCT220 | Obesity +1 | Active Not Recruiting | Q4 2025 2025-11-25 | Completed · awaiting
Updated 4mo ago
| NCT06939296 |
| Eli Lilly and Company | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Asset: Orforglipron | Obesity +1 | Completed | Q4 2025 2025-11-21 | Completed · awaiting
Updated 7mo ago
| NCT06584916 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes Mellitus | Completed | Q4 2025 2025-11-19 | Completed · awaiting
Updated 6mo ago
| NCT06065540 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab | Psoriatic Arthritis +1 | Completed | Q4 2025 2025-11-18 | Completed · awaiting
Updated 6mo ago
| NCT06588296 |
| Eli Lilly and Company | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Asset: Retatrutide | Obesity +2 | Completed | Q4 2025 2025-11-14 | Completed · awaiting
Updated 6mo ago
| NCT05931367 |
| Boryung Pharmaceutical Co., Ltd | A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C Asset: BR1018A | Essential Hypertension +1 | Completed | Q4 2025 2025-11-11 | Completed · awaiting
Updated 8mo ago
| NCT06165250 |
| Daewon Pharmaceutical Co., Ltd. | Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A Asset: DW5421A | Primary Hypercholesterolemia +1 | Completed | Q4 2025 2025-10-21 | Completed · awaiting
Updated 4mo ago
| NCT07444762 |
| Novo Nordisk A/S | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Asset: Semaglutide | Obesity | Active Not Recruiting | Q4 2025 2025-10-15 | Completed · awaiting
Updated 3mo ago
| NCT05726227 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) | Obesity +1 | Completed | Q4 2025 2025-10-09 | Completed · awaiting
Updated 3mo ago
| NCT06309992 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Asset: Cagrilintide | Type 2 Diabetes | Completed | Q4 2025 2025-10-01 | Completed · awaiting
Updated 4mo ago
| NCT06323174 |
| Eli Lilly and Company | A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Asset: Orforglipron | Type 2 Diabetes | Completed | Q3 2025 2025-09-26 | Completed · awaiting
Updated 9mo ago
| NCT06192108 |
| Jiangsu HengRui Medicine Co., Ltd. | A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes Asset: HR17031 injection | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | Completed | Q3 2025 2025-09-19 | Completed · awaiting
Updated 6mo ago
| NCT06881264 |
| Innovent Biologics (Suzhou) Co. Ltd. | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity Asset: IBI362 | Type 2 Diabetes +1 | Completed | Q3 2025 2025-09-17 | Completed · awaiting
Updated 5mo ago
| NCT06184568 |
| Eli Lilly and Company | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor Asset: Orforglipron | Type 2 Diabetes | Completed | Q3 2025 2025-09-15 | Completed · awaiting
Updated 9mo ago
| NCT06109311 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin Asset: Cagrilintide | Type 2 Diabetes | Completed | Q3 2025 2025-09-09 | Completed · awaiting
Updated 8mo ago
| NCT06323161 |
| Dong-A ST Co., Ltd. | Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control Asset: DA5221-T1 | Type 2 Diabetes | Active Not Recruiting | Q3 2025 2025-09-05 | Completed · awaiting
Updated 8mo ago
| NCT06290349 |
| Regeneron Pharmaceuticals | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) Asset: Aflibercept 8 mg | Neovascular Age-Related Macular Degeneration +1 | Active Not Recruiting | Q3 2025 2025-08-26 | Completed · awaiting
Updated 9mo ago
| NCT06491914 |
| Beijing Suncadia Pharmaceuticals C… | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia Asset: SHR-1918 | Homozygous Familial Hypercholesterolemia | Completed | Q3 2025 2025-08-25 | Completed · awaiting
Updated 7mo ago
| NCT06723652 |
| Eli Lilly and Company | A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Asset: Orforglipron | Type 2 Diabetes | Completed | Q3 2025 2025-08-22 | Completed · awaiting
Updated 10mo ago
| NCT06045221 |
| Bayer | A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes Asset: Finerenone | Chronic Kidney Disease +1 | Completed | Q3 2025 2025-08-20 | Completed · awaiting
Updated 9mo ago
| NCT05901831 |
| Laboratorios Sophia S.A de C.V. | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema Asset: Bevacizumab | Diabetic Macular Edema | Completed | Q3 2025 2025-08-18 | Completed · awaiting
Updated 4mo ago
| NCT05217680 |
| Eli Lilly and Company | A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes Asset: Orforglipron | Obesity +2 | Completed | Q3 2025 2025-08-08 | Completed · awaiting
Updated 10mo ago
| NCT05872620 |
| JW Pharmaceutical | Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia Asset: JW0108 + C2407 | Dyslipidemia | Completed | Q3 2025 2025-07-30 | Completed · awaiting
Updated 10mo ago
| NCT06955104 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight Asset: survodutide | Obesity +1 | Completed | Q3 2025 2025-07-29 | Completed · awaiting
Updated 5mo ago
| NCT06214741 |
| Merck Sharp & Dohme LLC | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Asset: Enlicitide Decanoate | Hypercholesterolemia +1 | Completed | Q3 2025 2025-07-28 | Completed · awaiting
Updated 10mo ago
| NCT05952856 |
| Eli Lilly and Company | A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Asset: Orforglipron | Obesity +2 | Active Not Recruiting | Q3 2025 2025-07-25 | Completed · awaiting
Updated 8mo ago
| NCT05869903 |
Upcoming metabolic readouts — next 12 months
· 70Industry Phase 3 metabolic trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| EMS | Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus Asset: MADALENA ASSOCIATION | Type 2 Diabetes Mellitus | Recruiting | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT04670666 |
| EMS | Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Asset: PIEMONTE | Type II Diabetes | Recruiting | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT05028140 |
| BrightGene Bio-Medical Technology … | A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia Asset: BGM0504 | Type 2 Diabetes (T2DM) | Recruiting | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT07064486 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects Asset: TQF3510 (Semaglutide Injection) | Obesity | Not Yet Recruiting | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 19mo ago
| NCT06738979 |
| Innovent Biologics (Suzhou) Co. Ltd. | Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Asset: IBI362 | Overweight +2 | Recruiting | Q3 2026 2026-08-01 (est.) | Estimated · fresh
Updated 4mo ago
| NCT07469800 |
Unlock 65 more metabolic readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.